21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
22:28 , May 6, 2019 |  BC Extra  |  Company News

Management tracks: Batu, Halozyme, FOG

Immunotherapy company Batu Biologics Inc. , (San Diego, Calif.) said founder Thomas Ichim has become president and CEO. Ichim, also a director, was previously Batu's CSO. He succeeds founder Samuel Wagner, who stepped down and...
23:22 , Apr 9, 2019 |  BC Extra  |  Company News

IFM Tre deal offers glimpse into Novartis' M&A future

Novartis' acquisition of IFM Tre gives a glimpse of its M&A strategy going forward, as the pharma focuses on early stage deals and aims to keep M&A spending at 5% of market cap. Prakash Raman,...
20:38 , Apr 9, 2019 |  BC Extra  |  Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
20:46 , Dec 21, 2018 |  BC Week In Review  |  Company News

CFIUS gives Novartis, Endocyte deal a pass -- for now

A Dec. 14 decision by CFIUS to neither clear nor initiate review of the $2.1 billion acquisition of Endocyte Inc. (NASDAQ:ECYT) by Novartis AG (NYSE:NVS; SIX:NOVN) provides little clarity as to how far the committee...
00:43 , Dec 19, 2018 |  BC Extra  |  Company News

CFIUS gives Novartis, Endocyte deal a pass -- for now

A decision by CFIUS to neither clear nor initiate review of a proposed $2.1 billion acquisition of Endocyte Inc. (NASDAQ:ECYT) by Novartis AG (NYSE:NVS; SIX:NOVN) provides little clarity as to how far the committee will...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest combinations of bispecific small molecules targeting fluorescein and CAIX, PSMA or FOLR1 plus anti-fluorescein CAR T cells could help treat triple-negative breast cancer (TNBC). The bispecific adapter molecules consist...
18:08 , Oct 19, 2018 |  BC Week In Review  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...
17:47 , Oct 18, 2018 |  BC Extra  |  Company News

Novartis buys Endocyte for $2.1B, gets radioligand therapy for prostate cancer

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire cancer company Endocyte Inc. (NASDAQ:ECYT) for about $2.1 billion in cash. The deal gives Novartis 177Lu-PSMA-617, a radioligand therapy in the Phase III VISION trial to treat prostate-specific membrane...